(Reuters) - America is on the verge of a revolution in cancer detection that will allow patients to be screened for early-stage disease simply by providing a blood sample. The market for these DNA-based tests could be soon be tens of billions of...
Company: GALLERI BO BJERGGAARD I/S; ILLUMINA, INC.; FULLERTON TECHNOLOGY CO., LTD.; COVINGTON & BURLING LLP; GIBSON, DUNN & CRUTCHER LLP; GRAIL, INC.; GUARDANT HEALTH, INC.
News Subject: (Business Lawsuits & Settlements (1BU19); Business Litigation (1BU04); Business Management (1BU42); Corporate Events (1CR05); Legal (1LE33))
Industry: (Biotechnology (1BI78); Genetic Testing (1GE72); Healthcare (1HE06); Healthcare Practice Specialties (1HE49); Internal Medicine (1IN54); Molecular & Cellular Biology (1MO84); Oncology & Hematology (1ON95); Pharmaceuticals & Biotechnology (1PH13))
Region: (Americas (1AM92); Delaware (1DE13); North America (1NO39); U.S. Mid-Atlantic Region (1MI18); USA (1US73))
Other Indexing: (America; U.S. Federal Trade Commission; Galleri; Illumina Inc; FTC; Covington & Burling; Gibson, Dunn & Crutcher; Grail Inc; Guardant Health Inc) (Grail; Adi Ravel; Jeff Bezos; Jeffrey P. Bezos; Bill Gates; William Henry Gates; Administrative; Michael Chappell; Dale Michael Chappell)
Keywords: antitrust; health; litigation